Literature DB >> 7759078

Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins.

T Okumiya1, S Ishii, R Kase, S Kamei, H Sakuraba, Y Suzuki.   

Abstract

Five point mutations were identified in unrelated Japanese Fabry disease hemizygotes: three new missense mutations, C142Y (425 G-->A), A156V (467 C-->T), and L166V (496 C-->G) in exon 3; one new splice site mutation at the 3' end of the consensus sequence in exon 4; one previously reported nonsense mutation, W44X (131 G-->A). C142Y expressed 50% of the normal enzyme protein in COS-1 cells, but catalytic activity was not detected. Both A156V and L166V expressed significant amounts of residual enzyme activity (6.7% and 9.8%) and enzyme proteins (10% each), the latter were more thermolabile at neutral pH than at acid pH, in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759078     DOI: 10.1007/BF00223869

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  21 in total

1.  Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A.

Authors:  Y Nagao; H Nakashima; Y Fukuhara; M Shimmoto; A Oshima; Y Ikari; Y Mori; H Sakuraba; Y Suzuki
Journal:  Clin Genet       Date:  1991-03       Impact factor: 4.438

2.  An atypical variant of Fabry's disease with manifestations confined to the myocardium.

Authors:  W von Scheidt; C M Eng; T F Fitzmaurice; E Erdmann; G Hübner; E G Olsen; H Christomanou; R Kandolf; D F Bishop; R J Desnick
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

3.  Nucleotide sequence of the human alpha-galactosidase A gene.

Authors:  R Kornreich; R J Desnick; D F Bishop
Journal:  Nucleic Acids Res       Date:  1989-04-25       Impact factor: 16.971

4.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  A strategy to reveal high-frequency RFLPs along the human X chromosome.

Authors:  J Aldridge; L Kunkel; G Bruns; U Tantravahi; M Lalande; T Brewster; E Moreau; M Wilson; W Bromley; T Roderick
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

6.  Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease.

Authors:  H Sakuraba; A Oshima; Y Fukuhara; M Shimmoto; Y Nagao; D F Bishop; R J Desnick; Y Suzuki
Journal:  Am J Hum Genet       Date:  1990-11       Impact factor: 11.025

7.  Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene.

Authors:  H S Bernstein; D F Bishop; K H Astrin; R Kornreich; C M Eng; H Sakuraba; R J Desnick
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

8.  A case of Fabry's disease in a patient with no alpha-galactosidase A activity caused by a single amino acid substitution of Pro-40 by Ser.

Authors:  T Koide; M Ishiura; K Iwai; M Inoue; Y Kaneda; Y Okada; T Uchida
Journal:  FEBS Lett       Date:  1990-01-01       Impact factor: 4.124

9.  Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease.

Authors:  C M Eng; L A Resnick-Silverman; D J Niehaus; K H Astrin; R J Desnick
Journal:  Am J Hum Genet       Date:  1993-12       Impact factor: 11.025

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  21 in total

1.  Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.

Authors:  Fumiko Matsuzawa; Sei-ichi Aikawa; Hirofumi Doi; Toshika Okumiya; Hitoshi Sakuraba
Journal:  Hum Genet       Date:  2005-05-28       Impact factor: 4.132

2.  High incidence of later-onset fabry disease revealed by newborn screening.

Authors:  Marco Spada; Severo Pagliardini; Makiko Yasuda; Turgut Tukel; Geetha Thiagarajan; Hitoshi Sakuraba; Alberto Ponzone; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2006-04-28       Impact factor: 11.025

3.  Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.

Authors:  Caterina Porto; Antonio Pisani; Margherita Rosa; Emma Acampora; Valeria Avolio; Maria Rosaria Tuzzi; Bianca Visciano; Cristina Gagliardo; Serena Materazzi; Giancarlo la Marca; Generoso Andria; Giancarlo Parenti
Journal:  J Inherit Metab Dis       Date:  2011-12-21       Impact factor: 4.982

4.  The molecular basis of pharmacological chaperoning in human α-galactosidase.

Authors:  Abigail I Guce; Nathaniel E Clark; Jerome J Rogich; Scott C Garman
Journal:  Chem Biol       Date:  2011-12-23

5.  Beta-galactosidase deficiency: an approach to chaperone therapy.

Authors:  Yoshiyuki Suzuki
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

6.  Alpha-galactosidase transgenic mouse: heterogeneous gene expression and posttranslational glycosylation in tissues.

Authors:  S Ishii; R Kase; H Sakuraba; C Taya; H Yonekawa; T Okumiya; Y Matsuda; K Mannen; M Takeshita; Y Suzuki
Journal:  Glycoconj J       Date:  1998-06       Impact factor: 2.916

7.  Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.

Authors:  Junichiro Matsuda; Osamu Suzuki; Akihiro Oshima; Yoshie Yamamoto; Akira Noguchi; Kazuhiro Takimoto; Masayuki Itoh; Yuji Matsuzaki; Yosuke Yasuda; Seiichiro Ogawa; Yuko Sakata; Eiji Nanba; Katsumi Higaki; Yoshimi Ogawa; Lika Tominaga; Kousaku Ohno; Hiroyuki Iwasaki; Hiroshi Watanabe; Roscoe O Brady; Yoshiyuki Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

8.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

9.  The AG dinucleotide terminating introns is important but not always required for pre-mRNA splicing in the maize endosperm

Authors: 
Journal:  Plant Physiol       Date:  1999-05       Impact factor: 8.340

10.  Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations.

Authors:  Patrícia Varela; Gerson Carvalho; Renan Paulo Martin; João Bosco Pesquero
Journal:  Metab Brain Dis       Date:  2020-11-06       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.